Targeting the Right Target: Epidermal Growth Factor Receptor–Directed Individualized Therapy

References

1. • Amado R
   • Wolf M
   • Freeman D
   • et al.
   Analysis of KRAS mutations in patients with metastatic colorectal cancer receiving panitumumab monotherapy.
   Eur J Cancer. 2007; 5 (Abstract 7LB).: 8
   • Google Scholar
2. • De Roock W
   • De Schutter J
   • De Hertogh G
   • et al.
   KRAS mutations preclude tumor shrinkage of colorectal cancers treated with cetuximab.
   J Clin Oncol. 2007; 25 (Abstract 4132).: 196s
   • PubMed
   • Google Scholar
3. • Finocchiaro G
   • Cappuzzo F
   • Jänne P
   • et al.
   EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer.
   J Clin Oncol. 2007; 25 (Abstract 4021).: 168s
   • Google Scholar
4. • Khambata-Ford S
   • Garrett CR
   • Meropol NJ
   • et al.
   Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
   J Clin Oncol. 2007; 25: 3230-3237
   • Scopus (1033)
   • PubMed
   • Crossref
   • Google Scholar
5. • Hecht R
   • Chidiac T
   • Mitchell E
   • et al.
   An interim analysis of efficacy and safety from a randomized controlled trial of panitumumab with chemotherapy plus bevacizumab (Bev) for metastatic colorectal cancer (mCRC).
   Ann Oncol. 2007; 18 (Abstract 0-0033).: vii21
   • Google Scholar
6. • Van Cutsem E
   • Nowacki M
   • Lang I
   • et al.
   Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial.
   J Clin Oncol. 2007; 25 (Abstract 4000).: 164s
   • Google Scholar

7. Sobrero A, Fehrenbacher L, Rivera F, et al. Randomized phase III trial of cetuximab plus irinotecan vs irinotecan alone for metastatic colorectal cancer (mCRC) after failing prior oxaliplatin-based therapy: the EPIC trial. Presented at: 98th Annual Meeting of the American Association for Cancer Research; April 14-18, 2007; Los Angeles, CA.

   • Google Scholar
8. • Folprecht G
   • Grothey A
   • Alberts S
   • et al.
   Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates.
   Ann Oncol. 2005; 16: 1311-1319
   • Scopus (588)
   • PubMed
   • Crossref
   • Google Scholar